TODD STRATEGY GROUP

Lobbying for AMGEN INC. · Biotechnology company.

Filing 4th Quarter - Report

4th Quarter (Oct 1 - Dec 31) 2025 · District of Columbia · House · Senate · $80,000.00 income · posted Jan 20, 2026

Lobbying activity 3

Medicare/Medicaid

Medicare/Medicaid payment reform. Implementation of Inflation Reduction Act of 2022.

Health Issues

Prescription Drug Pricing Policy. Supply Chain Issues.

Taxation/Internal Revenue Code

Prescription drug pricing policy.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.